{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:24:50Z","timestamp":1792783490989,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T00:00:00Z","timestamp":1668643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T00:00:00Z","timestamp":1668643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Merck Zagreb Croatia"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s40120-022-00422-z","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T11:06:11Z","timestamp":1668683171000},"page":"25-37","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Treatment with Cladribine Tablets Beyond Year 4: A Position Statement by Southeast European Multiple Sclerosis Centers"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3360-1748","authenticated-orcid":false,"given":"Mario","family":"Habek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Drulovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Brecl Jakob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Barbov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ljiljana","family":"Radulovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0252-4778","authenticated-orcid":false,"given":"Cecilia","family":"Rajda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konrad","family":"Rejdak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Tur\u010d\u00e1ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,17]]},"reference":[{"key":"422_CR1","doi-asserted-by":"crossref","unstructured":"Reich DS, Lucchinetti CF, Calabresi PA. Multiple Sclerosis. Longo DL (eds). N Engl J Med. 2018;378:169\u201380.","DOI":"10.1056\/NEJMra1401483"},{"key":"422_CR2","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1177\/1352458520968811","volume":"26","author":"T Coetzee","year":"2020","unstructured":"Coetzee T, Thompson AJ. Atlas of MS 2020: informing global policy change. Mult Scler J. 2020;26:1807\u20138.","journal-title":"Mult Scler J"},{"key":"422_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3325\/cmj.2018.59.65","volume":"59","author":"T Benjak","year":"2018","unstructured":"Benjak T, \u0160tefan\u010di\u0107 V, Drau\u0161nik \u017d, Cerove\u010dki I, Rogini\u0107 D, Habek M, et al. Prevalence of multiple sclerosis in Croatia: data from national and non-governmental organization registries. Croat Med J. 2018;59:65\u201370.","journal-title":"Croat Med J"},{"key":"422_CR4","doi-asserted-by":"crossref","unstructured":"Iljicsov A, Milanovich D, Ajtay A, Oberfrank F, B\u00e1lint M, Dobi B, et al. Incidence and prevalence of multiple sclerosis in Hungary based on record linkage of nationwide multiple healthcare administrative data. Nicoletti A, editor. PLoS One. 2020;15:e0236432.","DOI":"10.1371\/journal.pone.0236432"},{"key":"422_CR5","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.euroneuro.2011.08.008","volume":"21","author":"A Gustavsson","year":"2011","unstructured":"Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21:718\u201379.","journal-title":"Eur Neuropsychopharmacol"},{"key":"422_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2018.03116","volume":"9","author":"H Lassmann","year":"2019","unstructured":"Lassmann H. Pathogenic mechanisms associated with different clinical courses of multiple sclerosis. Front Immunol. 2019;9:1\u201314.","journal-title":"Front Immunol"},{"key":"422_CR7","doi-asserted-by":"publisher","first-page":"175628642110667","DOI":"10.1177\/17562864211066751","volume":"15","author":"G Giovannoni","year":"2022","unstructured":"Giovannoni G, Popescu V, Wuerfel J, Hellwig K, Iacobaeus E, Jensen MB, et al. Smouldering multiple sclerosis: the \u2018real MS.\u2019 Ther Adv Neurol Disord. 2022;15:175628642110667.","journal-title":"Ther Adv Neurol Disord"},{"key":"422_CR8","doi-asserted-by":"crossref","unstructured":"Claflin SB, Broadley S, Taylor B V. The effect of disease modifying therapies on disability progression in multiple sclerosis: a systematic overview of meta-analyses. Front Neurol. 2019;9.","DOI":"10.3389\/fneur.2018.01150"},{"key":"422_CR9","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41582-020-0310-1","volume":"16","author":"JD L\u00fcnemann","year":"2020","unstructured":"L\u00fcnemann JD, Ruck T, Muraro PA, Bar-Or A, Wiendl H. Author correction: immune reconstitution therapies: concepts for durable remission in multiple sclerosis. Nat Rev Neurol. 2020;16:125\u2013125.","journal-title":"Nat Rev Neurol"},{"key":"422_CR10","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1007\/s13311-020-00847-0","volume":"17","author":"L Prosperini","year":"2020","unstructured":"Prosperini L, Mancinelli CR, Solaro CM, Nociti V, Haggiag S, Cordioli C, et al. Induction versus escalation in multiple sclerosis: a 10-year real world study. Neurotherapeutics. 2020;17:994\u20131004.","journal-title":"Neurotherapeutics"},{"key":"422_CR11","doi-asserted-by":"publisher","first-page":"175628642098213","DOI":"10.1177\/1756286420982134","volume":"14","author":"AJ Coles","year":"2021","unstructured":"Coles AJ, Arnold DL, Bass AD, Boster AL, Compston DAS, Fern\u00e1ndez \u00d3, et al. Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial. Ther Adv Neurol Disord. 2021;14:1756286420982134.","journal-title":"Ther Adv Neurol Disord"},{"key":"422_CR12","unstructured":"Mavenclad - Summary Of Product Characteristics [Internet]."},{"key":"422_CR13","doi-asserted-by":"publisher","first-page":"175628641985498","DOI":"10.1177\/1756286419854986","volume":"12","author":"O Stuve","year":"2019","unstructured":"Stuve O, Soelberg Soerensen P, Leist T, Giovannoni G, Hyvert Y, Damian D, et al. Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers. Ther Adv Neurol Disord. 2019;12:175628641985498.","journal-title":"Ther Adv Neurol Disord"},{"key":"422_CR14","doi-asserted-by":"crossref","unstructured":"Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, S\u00f8rensen PS, et al. A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis. N Engl J Med. Massachusetts MedSoc; 2010;362:416\u201326.","DOI":"10.1056\/NEJMoa0902533"},{"key":"422_CR15","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41582-019-0170-8","volume":"15","author":"D Rotstein","year":"2019","unstructured":"Rotstein D, Montalban X. Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. Nat Rev Neurol. 2019;15:287\u2013300.","journal-title":"Nat Rev Neurol"},{"key":"422_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1756286420935019","volume":"13","author":"PS S\u00f8rensen","year":"2020","unstructured":"S\u00f8rensen PS, Centonze D, Giovannoni G, Montalban X, Selchen D, Vermersch P, et al. Expert opinion on the use of cladribine tablets in clinical practice. Ther Adv Neurol Disord. 2020;13:1\u201317.","journal-title":"Ther Adv Neurol Disord"},{"key":"422_CR17","doi-asserted-by":"crossref","unstructured":"Hellwig K, Verdun di Cantogno E, Sabid\u00f3 M. A systematic review of relapse rates during pregnancy and postpartum in patients with relapsing multiple sclerosis. Ther Adv Neurol Disord. 2021;14:175628642110510.","DOI":"10.1177\/17562864211051012"},{"key":"422_CR18","doi-asserted-by":"crossref","unstructured":"Stangel M, Becker V, Elias-Hamp B, Havla J, Grothe C, Pul R, et al. Oral pulsed therapy of relapsing multiple sclerosis with cladribine tablets\u2014expert opinion on issues in clinical practice. Mult Scler Relat Disord. Elsevier B.V.; 2021;54:103075.","DOI":"10.1016\/j.msard.2021.103075"},{"key":"422_CR19","unstructured":"Froud J, St John F, Tallantyre, EC , Uzochukwu E, Harding K, Willis M, Anderson V, et al. UK multiple sclerosis registries project: disease modifying treatment durability. ABN VIRTUAL Meet. 2021;P125."},{"key":"422_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103633","volume":"59","author":"G Giovannoni","year":"2022","unstructured":"Giovannoni G, Leist T, Aydemir A, Di CEV. Long-term efficacy for patients receiving cladribine tablets in CLARITY\/CLARITY extension: primary results from 9\u201315 years of follow-up in the CLASSIC-MS study. Mult Scler Relat Disord. 2022;59: 103633.","journal-title":"Mult Scler Relat Disord"},{"key":"422_CR21","doi-asserted-by":"crossref","unstructured":"Patti F, Visconti A, Capacchione A, Roy S. Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS). 2020;1\u201310.","DOI":"10.1177\/1756286420922685"},{"key":"422_CR22","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s40120-022-00364-6","volume":"11","author":"M Petracca","year":"2022","unstructured":"Petracca M, Ruggieri S, Barbuti E, Ianniello A, Fantozzi R, Maniscalco GT, et al. Predictors of cladribine effectiveness and safety in multiple sclerosis: a real-world, multicenter, 2-year follow-up study. Neurol Ther. 2022;11:1193\u2013208.","journal-title":"Neurol Ther"},{"key":"422_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103755","volume":"61","author":"I Rauma","year":"2022","unstructured":"Rauma I, Viitala M, Kuusisto H, Atula S, Sipil\u00e4 JOT, Ryytty M, et al. Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study. Mult Scler Relat Disord. 2022;61: 103755.","journal-title":"Mult Scler Relat Disord"},{"key":"422_CR24","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1177\/1352458520921087","volume":"27","author":"N Lizak","year":"2021","unstructured":"Lizak N, Hodgkinson S, Butler E, Lechner-Scott J, Slee M, McCombe PA, et al. Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: an MSBase registry substudy. Mult Scler J. 2021;27:465\u201374.","journal-title":"Mult Scler J"},{"key":"422_CR25","doi-asserted-by":"crossref","unstructured":"Butzkueven H, Spelman T, Ozakbas S, Alroughani R, Terzi M, Hodgkinson S, et al. Real-world comparative effectiveness and persistence of cladribine tablets and other oral disease-modifying treatments for multiple sclerosis from GLIMPSE: results from the MSBase Registry (P12\u20134.003). Neurology. 2022;98(8 Sup):P12\u20134.003","DOI":"10.1212\/WNL.98.18_supplement.1373"},{"key":"422_CR26","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1177\/13524585211012227","volume":"28","author":"S Pfeuffer","year":"2022","unstructured":"Pfeuffer S, Rolfes L, Hackert J, Kleinschnitz K, Ruck T, Wiendl H, et al. Effectiveness and safety of cladribine in MS: real-world experience from two tertiary centres. Mult Scler J. 2022;28:257\u201368.","journal-title":"Mult Scler J"},{"key":"422_CR27","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.msard.2019.01.038","volume":"29","author":"G Comi","year":"2019","unstructured":"Comi G, Cook S, Giovannoni G, Rieckmann P, S\u00f8rensen PS, Vermersch P, et al. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. Mult Scler Relat Disord. 2019;29:168\u201374.","journal-title":"Mult Scler Relat Disord"},{"key":"422_CR28","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s40120-022-00339-7","volume":"11","author":"G Giovannoni","year":"2022","unstructured":"Giovannoni G, Mathews J. Cladribine tablets for relapsing-remitting multiple sclerosis: a clinician\u2019s review. Neurol Ther Springer Healthcare. 2022;11:571\u201395.","journal-title":"Neurol Ther Springer Healthcare"},{"key":"422_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/17562864211058298","volume":"14","author":"P Rieckmann","year":"2021","unstructured":"Rieckmann P, Centonze D, Giovannoni G, Hua LH, Oreja-Guevara C, Selchen D, et al. Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice. Ther Adv Neurol Disord. 2021;14:1\u201313.","journal-title":"Ther Adv Neurol Disord"},{"key":"422_CR30","first-page":"134","volume":"27","author":"G Giovannoni","year":"2021","unstructured":"Giovannoni G, Berger J, Leist T, Jack D, Galazka A, Nolting A, et al. Post-approval safety of cladribine tablets with particular reference to COVID-19 outcomes: an update. Mult Scler J SAGE Publ. 2021;27:134\u2013740.","journal-title":"Mult Scler J SAGE Publ"},{"key":"422_CR31","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000158","volume":"2","author":"J Pakpoor","year":"2015","unstructured":"Pakpoor J, Disanto G, Altmann DR, Pavitt S, Turner BP, Marta M, et al. No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine. Neurol Neuroimmunol Neuroinflam. 2015;2: e158.","journal-title":"Neurol Neuroimmunol Neuroinflam"},{"key":"422_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102572","volume":"46","author":"T Leist","year":"2020","unstructured":"Leist T, Cook S, Comi G, Montalban X, Giovannoni G, Nolting A, et al. Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis. Mult Scler Relat Disord. 2020;46: 102572.","journal-title":"Mult Scler Relat Disord"},{"key":"422_CR33","unstructured":"Aubagio\u2014summary of product characteristics [Internet]."},{"key":"422_CR34","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1111\/ene.15153","volume":"29","author":"I Adamec","year":"2022","unstructured":"Adamec I, Jovanovi\u0107 I, Krbot Skori\u0107 M, Habek M. Double immune reconstitution therapy: cladribine after alemtuzumab in the treatment of multiple sclerosis. Eur J Neurol. 2022;29:901\u20134.","journal-title":"Eur J Neurol"},{"key":"422_CR35","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1177\/1352458517727603","volume":"24","author":"G Giovannoni","year":"2018","unstructured":"Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan K, Rieckmann P, Comi G, et al. Safety and efficacy of cladribine tablets in patients with relapsing\u2013remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study. Mult Scler J. 2018;24:1594\u2013604.","journal-title":"Mult Scler J"},{"key":"422_CR36","doi-asserted-by":"crossref","unstructured":"Giovannoni G, Singer BA, Issard D, Jack D, Vermersch P. Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: the CLARITY extension study. Mult Scler J. 2021;1\u201310.","DOI":"10.1177\/13524585211049392"},{"key":"422_CR37","doi-asserted-by":"crossref","unstructured":"Giovannoni G, Comi G, Rammohan K, Rieckmann P, Dangond F, Keller B, et al. Long-term disease stability assessed by the expanded disability status scale in patients treated with cladribine tablets 3.5\u00a0mg\/kg for relapsing multiple sclerosis: an exploratory post hoc analysis of the CLARITY and CLARITY extension studies. Adv Ther. Springer Healthcare; 2021;38:4975\u201385.","DOI":"10.1007\/s12325-021-01865-w"},{"key":"422_CR38","doi-asserted-by":"publisher","first-page":"5207","DOI":"10.3390\/jcm10215207","volume":"10","author":"K Rejdak","year":"2021","unstructured":"Rejdak K, Zasybska A, Pietruczuk A, Baranowski D, Szklener S, Kaczmarek M, et al. Long-term safety and efficacy of subcutaneous cladribine used in increased dosage in patients with relapsing multiple sclerosis: 20-year observational study. J Clin Med. 2021;10:5207.","journal-title":"J Clin Med"},{"key":"422_CR39","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1080\/14656566.2020.1792885","volume":"21","author":"SG Meuth","year":"2020","unstructured":"Meuth SG, Bayas A, Kallmann B, Kleinschnitz C, Linker R, Rieckmann P, et al. Long-term management of multiple sclerosis patients treated with cladribine tablets: an expert opinion. Expert Opin Pharmacother. 2020;21:1965\u20139.","journal-title":"Expert Opin Pharmacother"},{"key":"422_CR40","doi-asserted-by":"publisher","first-page":"4345","DOI":"10.1080\/21645515.2021.1969850","volume":"17","author":"T Gabeli\u0107","year":"2021","unstructured":"Gabeli\u0107 T, Barun B, Adamec I, Krbot Skori\u0107 M, Habek M. Product review on MAbs (alemtuzumab and ocrelizumab) for the treatment of multiple sclerosis. Hum Vaccin Immunother. 2021;17:4345\u201362.","journal-title":"Hum Vaccin Immunother"},{"key":"422_CR41","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jneuroim.2017.10.009","volume":"313","author":"S Rolla","year":"2017","unstructured":"Rolla S, De Mercanti SF, Bardina V, Horakova D, Habek M, Adamec I, et al. Lack of CD4 + T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses. J Neuroimmunol. 2017;313:89\u201391.","journal-title":"J Neuroimmunol"},{"key":"422_CR42","doi-asserted-by":"crossref","unstructured":"Rolla S, De Mercanti SF, Bardina V, Maglione A, Taverna D, Novelli F, et al. Long-term effects of alemtuzumab on CD4+ lymphocytes in multiple sclerosis patients: a 72-month follow-up. Front Immunol. 2022;13.","DOI":"10.3389\/fimmu.2022.818325"},{"key":"422_CR43","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000360","volume":"4","author":"D Baker","year":"2017","unstructured":"Baker D, Herrod SS, Alvarez-Gonzalez C, Zalewski L, Albor C, Schmierer K. Both cladribine and alemtuzumab may effect MS via B-cell depletion. Neurol Neuroimmunol Neuroinflam. 2017;4: e360.","journal-title":"Neurol Neuroimmunol Neuroinflam"},{"key":"422_CR44","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1002\/acn3.51206","volume":"7","author":"T Moser","year":"2020","unstructured":"Moser T, Schwenker K, Seiberl M, Feige J, Akg\u00fcn K, Haschke-Becher E, et al. Long-term peripheral immune cell profiling reveals further targets of oral cladribine in MS. Ann Clin Transl Neurol. 2020;7:2199\u2013212.","journal-title":"Ann Clin Transl Neurol"},{"key":"422_CR45","doi-asserted-by":"crossref","unstructured":"Meuth SG, Bayas A, Kallmann B, Linker R, Rieckmann P, Wattjes MP, et al. Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4. Expert Opin Pharmacother. 2022;1\u20138.","DOI":"10.1080\/14656566.2022.2106783"},{"key":"422_CR46","doi-asserted-by":"crossref","unstructured":"Meca-Lallana V, Garc\u00eda Dom\u00ednguez JM, L\u00f3pez Ruiz R, Mart\u00edn-Mart\u00ednez J, Ar\u00e9s Luque A, Hern\u00e1ndez P\u00e9rez MA, et al. Expert-agreed practical recommendations on the use of cladribine. Neurol Ther. 2022.","DOI":"10.1007\/s40120-022-00394-0"},{"key":"422_CR47","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/1352458517751049","volume":"24","author":"X Montalban","year":"2018","unstructured":"Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, et al. ECTRIMS\/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler J. 2018;24:96\u2013120.","journal-title":"Mult Scler J"},{"key":"422_CR48","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3325\/cmj.2022.63.379","volume":"63","author":"M Habek","year":"2022","unstructured":"Habek M, Adamec I, Barun B, Ba\u0161i\u0107 Kes V, Bogoje Raspopovi\u0107 A, Duka Glavor K, et al. Treatment of relapsing multiple sclerosis\u2014recommendations of the Croatian Neurological Society. Croat Med J. 2022;63:379\u201388.","journal-title":"Croat Med J"},{"key":"422_CR49","first-page":"1","volume":"12","author":"CC Hsu","year":"2007","unstructured":"Hsu CC, Sandford B. The delphi technique: making sense of consensus. Pract Assess Res Eval. 2007;12:1\u20138.","journal-title":"Pract Assess Res Eval"},{"key":"422_CR50","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S1474-4422(21)00095-8","volume":"20","author":"MP Wattjes","year":"2021","unstructured":"Wattjes MP, Ciccarelli O, Reich DS, Banwell B, de Stefano N, Enzinger C, et al. 2021 MAGNIMS\u2013CMSC\u2013NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol. 2021;20:653\u201370.","journal-title":"Lancet Neurol"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-022-00422-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-022-00422-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-022-00422-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T20:05:31Z","timestamp":1728417931000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-022-00422-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,17]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["422"],"URL":"https:\/\/doi.org\/10.1007\/s40120-022-00422-z","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,17]]},"assertion":[{"value":"29 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}